High-grade glioma, an aggressive form of pediatric and adult brain cancer, is challenging to treat given the tumor location, incidence of recurrence and difficulty for drugs to cross the blood-brain ...
DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...
12d
News-Medical.Net on MSNNew targeted therapy shows early success in treating pediatric high-grade gliomasAn international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a ...
12d
Macon Telegraph on MSN‘Lit up any room.’ Macon community mourns 9-year-old who died from rare brain cancerThe Macon-Bibb community is mourning the loss of a 9-year-old who was diagnosed with a rare brain disease. Kevin Lobello, a ...
The cancer is H3 K27M-mutant diffuse glioma, a high-grade glioma that affects children and young adults. While surgery is a treatment option for brain cancers, it’s usually risky for H3 K27M ...
6d
News Medical on MSNStudy identifies PDGFRA as a potential target for pediatric high-grade gliomasPediatric high-grade gliomas, particularly H3K27M diffuse midline gliomas (DMG), are aggressive malignant brain tumors with a poor prognosis.
11h
South Wales Argus on MSNMoney for Welsh projects researching brain tumour treatmentsUse precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
“Although glioma is largely associated with mutational processes that correlate with age, our finding that some gliomas have tumor signatures associated with environmental agents, such as ...
Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platformFiled IND in ...
Diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors found in the pontine region of the brainstem.
A recent study published in MedComm – Future Medicine by a research team from Fudan University provides an in-depth ...
Calidi (CLDI) continues to make great progress on all three of our platforms;our systemic asset CLD-400 proved it can deliver a gene therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results